Primary care docs prefer rep-delivered samples, says study

Share this article:

Despite busier schedules and less time for a detail, most primary care physicians (PCPs) prefer to receive samples directly from a sales rep, in person, according to a DTW Marketing Research study.

The study, which surveyed 100 PCPs online, found that 73% of the respondents favored samples hand-delivered from a rep, versus 20% who said they preferred online e-sampling. Additionally, 75% of a given PCP's current samples had arrived via sales rep, compared with 15% of samples coming from an online request, according to survey results.

In a release on the study, Christine Alongi, VP competitive intelligence services at DTW, said the findings should “serve as a word of caution to marketers considering major changes in their sampling programs,” since e-sampling “may prove to be cost-efficient, [but] the end result could negatively affect the overall promotional mix for the brand.”

In June, Michael du Toit, EVP, client service and new business at Digitas Health, told MM&M that online e-sampling programs have been a boon for pharmaceutical companies, resulting in “an increase of sample requisition” by doctors. “The experience we've had with our clients has been that sample consumption went up,” as a result of e-sampling, du Toit said.

Algoni said the DTW study did not look at total sample requests and quantities among doctors receiving sales reps, compared with doctors using e-sampling programs.                

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...